NASDAQ · ASTH
Healthcare · Medical - Care Facilities
$38.35
Down-$1.25 (-3.16%)
Updated Sep 16, 2026, 5:48 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ASTH closed at $38.35 after 20 trading sessions, down 2.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $39.70 | $39.70 | $38.00 | $38.35 | 314.33K |
| Sep 14, 2026 | $38.21 | $39.95 | $38.21 | $39.60 | 321.27K |
| Sep 11, 2026 | $38.45 | $38.88 | $37.585 | $37.98 | 191.72K |
| Sep 10, 2026 | $38.06 | $39.40 | $37.48 | $38.03 | 264.19K |
| Sep 9, 2026 | $37.87 | $38.20 | $36.66 | $38.06 | 197.07K |
| Sep 8, 2026 | $38.195 | $38.28 | $37.24 | $38.10 | 304.98K |
| Sep 4, 2026 | $37.65 | $39.24 | $37.2182 | $38.47 | 241.95K |
| Sep 3, 2026 | $38.80 | $38.945 | $37.53 | $37.83 | 380.28K |
| Sep 2, 2026 | $38.71 | $39.235 | $38.44 | $38.57 | 305.49K |
| Sep 1, 2026 | $38.04 | $39.39 | $37.69 | $38.60 | 301.33K |
| Aug 31, 2026 | $37.63 | $38.61 | $37.505 | $38.11 | 235.23K |
| Aug 28, 2026 | $38.46 | $38.68 | $37.66 | $37.96 | 368.7K |
| Aug 27, 2026 | $38.27 | $38.59 | $37.5311 | $38.41 | 281.24K |
| Aug 26, 2026 | $37.64 | $39.36 | $37.07 | $38.61 | 281.14K |
| Aug 25, 2026 | $38.11 | $38.11 | $36.6001 | $37.61 | 362.72K |
| Aug 24, 2026 | $39.18 | $39.8545 | $37.90 | $38.11 | 371.37K |
| Aug 21, 2026 | $38.90 | $39.44 | $38.43 | $39.35 | 395.14K |
| Aug 20, 2026 | $39.12 | $39.89 | $38.52 | $38.74 | 214.31K |
| Aug 19, 2026 | $39.71 | $41.00 | $39.13 | $39.40 | 384.5K |
| Aug 18, 2026 | $39.73 | $40.545 | $38.76 | $39.16 | 357.97K |
The latest Smart Investors Daily articles mentioning ASTH.
ASTH research
Company profile and research snapshot.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 7, 2026 | Barclays | Overweight | — |
| Jul 14, 2026 | TD Cowen | Buy | — |
| Jul 14, 2026 | BTIG | Buy | — |
| Jun 2, 2026 | BTIG | Buy | — |
Generated Sep 16, 2026, 11:02 AM
Astrana Health shares declined 3.16% today despite receiving a bullish initiation from a major analyst firm, suggesting broader market headwinds are outweighing positive catalysts. The stock is navigating mixed signals as analyst attention increases but investor sentiment remains cautious in the near term.
Bottom line: While Astrana Health received validation from Oppenheimer's Outperform initiation and $53 price target—suggesting meaningful upside potential—today's 3.16% decline reflects near-term caution that may be unrelated to the positive analyst catalyst. Investors should view this dip as a potential entry point if they believe in the company's competitive advantages, but should monitor execution on operational metrics and cost management in the coming quarters.
Yahoo · Sep 15, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Benzinga · Sep 15, 2026
Oppenheimer analyst Michael Wiederhorn initiates coverage on Astrana Health (NASDAQ:ASTH) with a Outperform rating and announces Price Target of $53.
SeekingAlpha · Aug 12, 2026
Astrana Health (ASTH) buy thesis: 46% peer discount, Care Enablement margins, capitation-led growth, and $48 PT (+28%).
Benzinga · Aug 11, 2026
Truist Securities analyst Jailendra Singh maintains Astrana Health (NASDAQ:ASTH) with a Buy and raises the price target from $47 to $55.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ASTH.
